Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds
Executive Summary
Bristol-Myers Squibb has taken a beating over setbacks for its Opdivo and its immuno-oncology portfolio, but a settlement reached with Merck over Keytruda’s patent infringement is a momentary victory for the PD-1 pioneer.
You may also be interested in...
Ono, PD-1 Discoverer Settle Long-Running Patent Dispute
Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund.
Opdivo Secures India Patent, Fends Off Multi-Party Opposition
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial
Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.